Pharmaron Beijing Co., Ltd. Announces RMB 3 Billion Investment in Shaoxing API Manufacturing Facility
Pharmaron Beijing Co., Ltd. (Stock Code: 3759) has voluntarily disclosed a significant strategic investment in the construction of a large-scale pharmaceutical manufacturing facility in Shaoxing, Zhejiang Province. The new facility, to be developed via its wholly-owned subsidiary Pharmaron (Shaoxing) API Manufacturing Co., Ltd., marks a major step in expanding the company’s production of high-end pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
Key Highlights for Investors
- Strategic Expansion: Pharmaron plans to acquire approximately 253 mu of land in Shaoxing City Hangzhou Bay Shangyu Economic and Technological Development Zone, with the intention to construct a facility capable of producing 200 tonnes per annum of pharmaceutical intermediates and APIs. The products will include intermediates and APIs for obesity, diabetes, oncology, and other therapeutic areas.
- Investment Details: The total investment for the project is estimated at RMB 3.0 billion. This includes land acquisition, construction costs, procurement of equipment and analytical instruments, and development of supporting public facilities.
- Phased Construction: The facility will be developed in two phases. Phase I is expected to be operational by 2028, with Phase II anticipated to commence in 2030, subject to actual construction progress.
- Board Approval: The project was approved by Pharmaron’s Board of Directors on May 26, 2026, and does not require shareholder approval, as it falls within the Board’s authority.
- Strengthening CDMO Capabilities: The facility will enhance Pharmaron’s contract development and manufacturing organisation (CDMO) services, supporting activities from pre-clinical R&D to commercial manufacturing. It will also strengthen the company’s application of green manufacturing technologies.
- Market Impact: The project is designed to consolidate Pharmaron’s core business foundation, strengthen its competitive advantages, and expand market share in the high-end pharmaceutical intermediates and APIs sector.
Potential Price Sensitive Information
- Scale and Timing: The RMB 3 billion investment is substantial and could significantly affect Pharmaron’s future profitability and strategic positioning. However, the company states that the project is not expected to materially impact financial results for the year ending December 31, 2026. The actual effect on future operating results will depend on construction progress and order volumes.
- Risks: The report warns of several risks, including uncertainties in industry development trends, market conditions, and management capability. Risks related to project establishment, land acquisition, environmental protection, planning, and construction approvals could cause delays, modifications, suspension, or termination. Macroeconomic factors, capital raising, and credit policies may also affect funding and progress.
- Disclosure Commitments: Pharmaron emphasizes its commitment to comply with the Hong Kong Stock Exchange’s Listing Rules for further disclosures, reporting, and, if necessary, shareholder approval as the project progresses.
- Warning Statement: Investors should note that drug production and sales are susceptible to uncertainties arising from policy changes, market environment shifts, and medication demand. The project’s approval process may also be subject to delays or termination.
Benefits and Strategic Rationale
- Long-term Growth: The Board believes this investment will accelerate Pharmaron’s strategic objectives, enhance future profitability, and positively impact long-term business development.
- Integrated Services Platform: The new facility will advance Pharmaron’s end-to-end, fully integrated, and multi-modal services platform, positioning the company as a leader in CDMO services for high-value pharmaceutical products.
- Resource Coordination: Pharmaron intends to strengthen market research and resource coordination to mitigate risks and ensure successful implementation.
Board Composition
The Board currently comprises Dr. Lou Boliang (Chairman), Mr. Lou Xiaoqiang, Ms. Zheng Bei (executive Directors), Mr. Li Shing Chung Gilbert (employee representative Director), Mr. Li Jiaqing, Ms. Wan Xuan (non-executive Directors), and Ms. Li Lihua, Mr. Yu Jian, Prof. Tsang King Fung (independent non-executive Directors).
Advisory to Shareholders and Investors
Given the project’s scale, potential impact, and associated risks, shareholders and investors are advised to exercise caution and closely monitor subsequent disclosures regarding the Shaoxing project’s progress. The outcome of this investment may be material to Pharmaron’s future performance and share value.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as described above. Investors are encouraged to conduct their own research and consult professional advisors before making investment decisions.
華蘭北京有限公司宣佈於紹興建設新藥物中間體及API生產基地，投資額達30億元人民幣
華蘭北京有限公司（股份代號：3759）自願披露一項重大战略性投資，計劃於浙江省紹興市通過全資子公司華蘭（紹興）藥物製造有限公司建設大型藥物中間體及原料藥（API）生產基地。此項目將顯著擴大公司高端藥物中間體及API的產能。
投資者需注意的重點
- 戰略擴張： 華蘭計劃於紹興市杭州灣上虞經濟技術開發區收購約253畝土地，建設年產量達200噸的藥物中間體及API生產基地，產品涵蓋治療肥胖、糖尿病、腫瘤及其他治療領域。
- 投資詳情： 項目總投資額預計為30億元人民幣，包含土地收購、建設費用、設備及分析儀器採購、配套公共設施建設等。
- 分期建設： 項目將分兩期建設，第一期預計於2028年投入運作，第二期預計於2030年啟用，具體進度取決於實際施工情況。
- 董事會批准： 該項目已於2026年5月26日獲董事會批准，屬董事會權限範圍，無需股東大會批准。
- 提升CDMO能力： 新基地將增強華蘭從臨床前研發到商業化生產的CDMO服務能力，並提升綠色製造技術的應用。
- 市場影響： 項目旨在鞏固華蘭核心業務基礎，增強競爭優勢，擴大高端藥物中間體及API市場份額。
可能影響股價的重要資訊
- 規模與時機： 30億元人民幣的投資金額巨大，或將顯著影響公司未來盈利及戰略地位。公司表示該項目預計不會對2026年底前財務狀況造成重大影響，實際效益將視建設進度及訂單情況而定。
- 風險提示： 報告指出，產業發展趨勢、管理團隊能力、市場條件等存在不確定性；項目涉及立項、土地、環保、規劃、施工等多項審批，或面臨延遲、變更、暫停或終止的風險。宏觀經濟、資金籌措及信貸政策亦可能影響資金及進度。
- 信息披露承諾： 華蘭承諾將根據香港交易所上市規則，適時進行進一步披露、報告及必要時的股東批准。
- 警示聲明： 投資者需留意，藥品生產及銷售易受政策、環境、需求等多重不確定性影響，項目審批過程亦或有延誤或終止風險。
項目收益及戰略理由
- 長遠增長： 董事會認為，此投資將加快公司戰略目標實現，提升未來盈利能力，對公司長遠發展帶來正面影響。
- 一體化服務平台： 新基地將進一步推動華蘭的端到端、一體化及多模式服務平台建設，鞏固其在高價值藥品CDMO領域的領導地位。
- 資源協調： 華蘭將加強市場調研和資源協調，積極防控相關風險，保障項目順利實施。
董事會組成
董事會現由主席樓伯良博士、樓曉強先生、鄭蓓女士（執行董事）、李成忠先生（職工代表董事）、李嘉慶先生、萬璇女士（非執行董事）、李麗華女士、余健先生、曾景峰教授（獨立非執行董事）組成。
對股東及投資者的建議
鑒於項目規模及潛在影響及相關風險，股東及潛在投資者應保持關注並審慎評估，密切留意後續披露。此項投資結果或對公司未來表現及股價產生重大影響。
免責聲明：
本文僅供參考，並不構成投資建議。所有前瞻性陳述均受上述風險及不確定性影響。投資者應自行研究及諮詢專業人士作出投資決策。
